Aspirin Dose Escalation for the Prevention of recurrent preterm delivery Trial- ADEPT
ADEPT - Aspirin study to prevent preterm delivery
Sponsor: Maternal Fetal Medicine Units Network - National Institute of Child Health and Human Development
Enrolling: Female Patients Only
Study Length: 8 Months
Clinic Visits: 8
IRB Number: AAAV7207
U.S. Govt. ID: NCT06980025
Contact: Megan Loffredo, MD: 12037221058 / ml4639@cumc.columbia.edu
Additional Study Information: We are conducting a research trial to determine if low dose Aspirin either 81 or 162 mg will preventpreterm birth in patients who have had a previous preterm birth, still birth, or complications of pregnancy including preeclampsia, small for gestational age baby, fetal growth restriction, or placental abruption. You will be randomized to 81 or 162 mg and take the study drug daily until 36 weeks and 6 days.
Investigator
Uma Reddy, MD, MPH
Do You Qualify?
Are you currently pregnant? Yes No
Are you receiving care and plan to deliver at Columbia? Yes No
Did you have a preterm delivery? Yes No
Do you have any reason you cannot take Aspirin? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Megan Loffredo, MD
ml4639@cumc.columbia.edu
12037221058
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE